Invest now
Cipla share price
Moderate risk
You have to be logged in to add this to Watchlist.- ₹1,431.85(0.13%)August 18, 2026 15:28:18 PM IST
- NSE
- BSE
- Vol : 601.56 K (NSE + BSE)Last 20 day avg : 1.40 M
Cipla is trading 0.13% upper at Rs 1,431.85 as compared to its last closing price. Cipla has been trading in the price range of 1,437.55 & 1,429.35. Cipla has given -5.28% in this year & -2.47% in the last 5 days. Cipla has TTM P/E ratio 35.11 as compared to the sector P/E of 32.90.There are 37 analysts who have initiated coverage on Cipla. There are 8 analysts who have given it a strong buy rating & 14 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 789.05 Crores in its last quarter.Listed peers of Cipla include Sun Pharmaceutical Industries (-0.32%), Divi's Laboratories (1.24%), Torrent Pharmaceuticals (1.63%).The Mutual Fund holding in Cipla was at 20.56% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Cipla was at 20.20% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 19 Aug 2026, 03:01 AM IST
- BetaLow volatility0.66Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldInline with the industry0.91Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation3.00The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Cipla News
Cipla Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,876.40 | -0.32 | 4,50,200.61 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,600.00 | 1.24 | 2,28,302.98 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,975.00 | 1.63 | 1,89,226.24 | 72.73 | 19.22 | 0.80 | 141.16 |
| Zydus Lifesciences | 1,117.00 | -1.33 | 1,11,421.17 | 21.19 | 4.24 | 0.09 | 14.22 |
| Lupin | 2,225.00 | -1.51 | 1,01,734.77 | 19.12 | 4.98 | 0.74 | 9.53 |
Mutual Fund Ownership
View allCipla Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-23 | Quarterly Results |
| 2026-05-13 | Audited Results & Final Dividend |
| 2026-01-23 | Quarterly Results |
| 2025-10-30 | Quarterly Results |
| 2025-07-25 | Quarterly Results |
About the company Cipla
- IndustryBiotechnology & Drugs
- ISININE059A01026
- BSE Code500087
- NSE CodeCIPLA
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
Cipla Share Price FAQs
Cipla is trading at 1431.85 as on Tue Aug 18 2026 09:58:18. This is 0.13% upper as compared to its previous closing price of 1430.00.
The market capitalization of Cipla is 115672.45 Cr as on Tue Aug 18 2026 09:58:18.
The average broker rating on Cipla is Buy. The breakup of analyst rating is given below -
- 8 analysts have given a strong buy rating
- 14 analysts have given a buy rating
- 11 analysts have given a hold rating
- 3 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Cipla is 1672.20 whereas the 52 wk low is 1165.55
Cipla can be analyzed on the following key metrics -
- TTM P/E: 35.11
- Sector P/E: 32.90
- Dividend Yield: 0.91%
- D/E ratio: -
Cipla reported a net profit of 3879.23 Cr in 2026.
The Mutual Fund Shareholding was 20.56% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Cipla QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.